【摘要】 目的研究氢氯噻嗪(HCTZ)对不同血管紧张素转化酶(ACE)基因型的原发性高血压患者血浆ACE浓度和血管紧张素Ⅱ(AngⅡ)浓度的影响。方法829例原发性高血压患者同时服用HCTZ12.5mg,qd。6周后资料完整的785例患者按II、ID、DD3种基因型分组,观测不同基因型间血浆ACE浓度、AngⅡ浓度的变化。结果服用HCTZ6周后II、ID、DD型患者血浆ACE浓度较服药前稍增高,但差异无统计学意义;血浆AngⅡ浓度分别升高到(85.56±64.68)、(81.97±57.99)和(80.84±67.96)ng/L,与服药前比较均差异有统计学意义。3组不同基因型患者血浆AngⅡ服药前后组间差异无统计学意义。结论服HCTZ后,3组基因型患者血浆AngⅡ浓度均升高,血浆ACE浓度不是影响血浆AngⅡ浓度的主要因素。更多还原

【Abstract】 Objective:To study the effect of hydrochlorothiadide on levels of plasma angiotensin-converting enzyme (ACE) and angiotensin Ⅱin essential hypertensive patients carrying different ACE genotypes. Method:Eight hundred and twenty-nine patients had taken HCTZ 12.5 mg/d for six weeks. At last,785 patients with full records were tested by polymerase chain reaction and then the change of plasma ACE and angiotensin Ⅱ were compared according to the different ACE genotypes.Result:After 6 weeks treatment, plasma AngⅡ levels in II, ID,DD genotypes were elevated to (85.56±64.68), (81.97±57.99) and ( 80.84±67.96)ng/L respectively. There were statistical significance compared to baseline levels in three genotypes respectively. There were no statistical significance with change of plasma ACE levels. Conclusion:The levels of plasma AngⅡ elevated after antihypertensive treatment by hydrochlorothiadide. Plasma AngⅡ levels did not affected by plasma ACE levels.更多还原